share_log

Cantor Fitzgerald Maintains Overweight on BridgeBio Pharma, Raises Price Target to $70

Benzinga ·  Mar 19 08:35

Cantor Fitzgerald analyst Josh Schimmer maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $60 to $70.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment